Aura Biosciences (AURA) Depreciation & Amortization (CF) (2020 - 2026)
Aura Biosciences' (AURA) quarterly Depreciation & Amortization (CF) came in at $300000.0 in Q1 2026, little changed YoY from $300000.0 in Q1 2025, and up 31.0% on a QoQ basis from $229000.0 in Q4 2025.
Aura Biosciences (AURA) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $300000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) changed 0.0% year-over-year to $300000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 5.92% YoY) and the FY2025 annual result came in at $1.1 million, down 5.92% from the prior year.
- Depreciation & Amortization (CF) advanced to $300000.0 in Q1 2026, from $229000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $400000.0 in Q3 2023 to a low of $229000.0 in Q4 2025.
- A 5-year average of $306117.6 and a median of $300000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 73.0% — and 2024, when it dropped 25.0%.
- Tracing AURA's Depreciation & Amortization (CF) over 5 years: stood at $346000.0 in 2022, then declined by 14.74% to $295000.0 in 2023, then advanced by 1.69% to $300000.0 in 2024, then dropped by 23.67% to $229000.0 in 2025, then jumped by 31.0% to $300000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $300000.0 (Q1 2026), $229000.0 (Q4 2025), and $300000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - | 300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 300,000.00 |
| Jun 30, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 229,000.00 |
| Dec 31, 2025 | 229,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2024 | 300,000.00 |
| Dec 31, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 306,000.00 |
| Mar 31, 2024 | 306,000.00 |